Peripheral neuropathy symptoms, pain, and functioning in previously treated multiple myeloma patients treated with selinexor, bortezomib, and dexamethasone
2021
Abstrakt
With over 34 000 new cases and ~12 400 deaths from multiple myeloma (MM) anticipated in 2021 in the United States and about twice as many in Europe, there is an unmet medical need for therapies in patients with previously treated MM that have progressed on available agents. Currently, there are few agents with new mechanisms of action approved for early-line treatment.
Selinexor (XPOVIO, Karyopharm Therapeutics Inc.) is a potent, oral, first-in-class, selective inhibitor of nuclear export that specifically blocks exportin 1 (XPO1).